Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BPTH Stock Summary
Top 10 Correlated ETFs
BPTH
In the News
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today's event is being recorded.
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.
Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call.
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.
Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call.
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 15, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023 and to provide a business overview.
Why Is Bio-Path (BPTH) Stock Down 12% Today?
Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.
Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call.
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 12, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.
BPTH Financial details
BPTH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -3.2 | -2.82 | -1.55 | -1.9 | -33.64 | |
Operating cash flow per share | -3.15 | -2.85 | -1.47 | -2.08 | -24.13 | |
Free cash flow per share | -3.15 | -2.85 | -1.49 | -2.08 | -24.13 | |
Cash per share | 7.69 | 3.58 | 3.54 | 1.43 | 2.2 | |
Book value per share | 7.94 | 3.92 | 3.79 | 1.95 | 0.92 | |
Tangible book value per share | 7.94 | 3.92 | 3.79 | 1.95 | 0.92 | |
Share holders equity per share | 7.94 | 3.92 | 3.79 | 1.95 | 0.92 | |
Interest debt per share | 0.16 | 0.09 | 0.03 | 0.03 | 0.24 | |
Market cap | 424.59M | 269.29M | 507.07M | 219.74M | 4.43M | |
Enterprise value | 404.58M | 255.87M | 483.53M | 209.57M | 3.49M | |
P/E ratio | -49.92 | -24.81 | -48.58 | -15.88 | -0.28 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -50.78 | -24.57 | -51.13 | -14.55 | -0.38 | |
PFCF ratio | -50.78 | -24.57 | -50.77 | -14.53 | -0.38 | |
P/B Ratio | 20.14 | 17.87 | 19.92 | 15.5 | 10.04 | |
PTB ratio | 20.14 | 17.87 | 19.92 | 15.5 | 10.04 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -47.81 | -23.79 | -47.03 | -15.27 | -0.22 | |
EV to operating cash flow | -48.39 | -23.35 | -48.76 | -13.88 | -0.3 | |
EV to free cash flow | -48.39 | -23.35 | -48.42 | -13.86 | -0.3 | |
Earnings yield | -0.02 | -0.04 | -0.02 | -0.06 | -3.63 | |
Free cash flow yield | -0.02 | -0.04 | -0.02 | -0.07 | -2.61 | |
Debt to equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.26 | |
Debt to assets | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | |
Net debt to EBITDA | 2.36 | 1.25 | 2.29 | 0.74 | 0.06 | |
Current ratio | 17.68 | 13.65 | 27.29 | 9.27 | 1.6 | |
Interest coverage | 0 | 0 | 0 | 421.24 | 0 | |
Income quality | 0.97 | 1.01 | 0.95 | 1.09 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.43 | -0.12 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 23.91 | 15.77 | 11.5 | 9.13 | 26.42 | |
ROIC | -0.39 | -0.69 | -0.4 | -0.95 | -23.75 | |
Return on tangible assets | -0.38 | -0.66 | -0.39 | -0.87 | -4.99 | |
Graham Net | 7.31 | 3.21 | 3.37 | 1.18 | -3.61 | |
Working capital | 20.75M | 14.79M | 25.18M | 13.93M | 1.14M | |
Tangible asset value | 21.09M | 15.07M | 25.46M | 14.17M | 441K | |
Net current asset value | 20.42M | 14.55M | 25.03M | 13.82M | 263K | |
Invested capital | 0.02 | 0.02 | 0.01 | 0.02 | 0.26 | |
Average receivables | 387.61K | 387.61K | -261.5 | -2.06K | -1.79K | |
Average payables | 649.5K | 293K | 103K | 386.5K | 562K | |
Average inventory | 388 | 1.02K | 898 | 2.06K | 1.79K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 771.26 | 241.72 | 240.31 | 1.37K | 937.11 | |
Days of inventory on hand | 1.23 | 3.08 | 1.19 | 7.36 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.47 | 1.51 | 1.52 | 0.27 | 0.39 | |
Inventory turnover | 296.39 | 118.62 | 307.84 | 49.62 | 0 | |
ROE | -0.4 | -0.72 | -0.41 | -0.98 | -36.46 | |
Capex per share | 0 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.54 | -0.66 | -0.53 | -0.32 | -5.46 | |
Operating cash flow per share | -0.69 | -0.46 | -0.41 | -0.28 | -2.94 | |
Free cash flow per share | -0.69 | -0.46 | -0.41 | -0.28 | -2.94 | |
Cash per share | 1.43 | 0.85 | 0.43 | 0.23 | 1.7 | |
Book value per share | 1.95 | 1.14 | 0.63 | 0.25 | 0.71 | |
Tangible book value per share | 1.95 | 1.14 | 0.63 | 0.25 | 0.71 | |
Share holders equity per share | 1.95 | 1.14 | 0.63 | 0.25 | 0.71 | |
Interest debt per share | 0.03 | 0.02 | 0.02 | 0.01 | 0.18 | |
Market cap | 219.74M | 221.29M | 283.38M | 74.39M | 5.72M | |
Enterprise value | 209.57M | 214.75M | 280.1M | 72.18M | 4.78M | |
P/E ratio | -13.92 | -10.53 | -16.73 | -5.81 | -0.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -43.95 | -60.58 | -86.21 | -26.75 | -3.15 | |
PFCF ratio | -43.95 | -60.58 | -86.21 | -26.75 | -3.15 | |
P/B Ratio | 15.5 | 24.3 | 56.19 | 29.46 | 12.98 | |
PTB ratio | 15.5 | 24.3 | 56.19 | 29.46 | 12.98 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -53.19 | -40.93 | -66.75 | -21.86 | -1.81 | |
EV to operating cash flow | -41.91 | -58.79 | -85.21 | -25.96 | -2.64 | |
EV to free cash flow | -41.91 | -58.79 | -85.21 | -25.96 | -2.64 | |
Earnings yield | -0.02 | -0.02 | -0.01 | -0.04 | -0.59 | |
Free cash flow yield | -0.02 | -0.02 | -0.01 | -0.04 | -0.32 | |
Debt to equity | 0.02 | 0.02 | 0.03 | 0.06 | 0.26 | |
Debt to assets | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 | |
Net debt to EBITDA | 2.58 | 1.25 | 0.78 | 0.67 | 0.35 | |
Current ratio | 9.27 | 5.65 | 4.39 | 3.54 | 1.6 | |
Interest coverage | 199.3 | 278.53 | 0 | 0 | 0 | |
Income quality | 1.26 | 0.69 | 0.78 | 0.87 | 0.54 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.88 | 4.12 | 2.75 | 1.34 | 9.36 | |
ROIC | -0.27 | -0.56 | -0.79 | -1.14 | -5 | |
Return on tangible assets | -0.25 | -0.47 | -0.65 | -0.64 | -1.05 | |
Graham Net | 1.18 | 0.59 | 0.25 | -0.01 | -2.79 | |
Working capital | 13.93M | 8.88M | 4.83M | 3.45M | 1.14M | |
Tangible asset value | 14.17M | 9.11M | 5.04M | 2.53M | 441K | |
Net current asset value | 13.82M | 8.8M | 4.78M | 2.31M | 263K | |
Invested capital | 0.02 | 0.02 | 0.03 | 0.06 | 0.26 | |
Average receivables | -2.97K | -2.99K | -1.73K | -534.5 | 0 | |
Average payables | 856.5K | 747K | 732.5K | 457.5K | 367K | |
Average inventory | 2.97K | 2.99K | 1.73K | 534.5 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.31K | 1.65K | 1.25K | 541.96 | 1K | |
Days of inventory on hand | 7.02 | 4.79 | 2.09 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.07 | 0.05 | 0.07 | 0.17 | 0.09 | |
Inventory turnover | 12.82 | 18.78 | 43.03 | 0 | 0 | |
ROE | -0.28 | -0.58 | -0.84 | -1.27 | -7.65 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BPTH Frequently Asked Questions
What is Bio-Path Holdings, Inc. stock symbol ?
Bio-Path Holdings, Inc. is a US stock , located in Bellaire of Tx and trading under the symbol BPTH
What is Bio-Path Holdings, Inc. stock quote today ?
Bio-Path Holdings, Inc. stock price is $4.04 today.
Is Bio-Path Holdings, Inc. stock public?
Yes, Bio-Path Holdings, Inc. is a publicly traded company.